Company
Alkermes
Alkermes has 19 drugs tracked on RxWires: 3 post-market, 6 in Phase 3, 1 in Phase 2/3, 6 in Phase 2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Aripiprazole Lauroxil | Post-Market | Schizophrenia |
| Naltrexone for extended-release injectable suspension | Post-Market | Opioid-Related Disorders |
| VIVITROL 380mg | Post-Market | Opioid Dependence |
| ALKS 5461 | Phase 3 | Refractory Major Depressive Disorder |
| Medisorb naltrexone 380 mg | Phase 3 | Opiate Dependence |
| ALKS 3831 | Phase 3 | Schizophrenia |
| Extended-Release Naltrexone | Phase 3 | Opiate Dependence |
| ALKS 2680 Dose 1 | Phase 3 | Narcolepsy Type 1 |
| OLZ/SAM | Phase 3 | Schizophrenia |
| ALKS 2680, 4mg | Phase 2/3 | Narcolepsy Type 1 |
| RDC-0313 (ALKS 33) | Phase 2 | Binge Eating Disorder |
| ALKS 7290 | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD) |
| N1539 | Phase 2 | Hysterectomy |
| ALKS 37 | Phase 2 | Opioid-induced Constipation |
| ALKS 7290 Dose | Phase 2 | Major Depressive Disorder (MDD) |
| Samidorphan + olanzapine (ALKS 3831) | Phase 2 | Schizophrenia |
| ALKS 9072, Low dose | Phase 1 | Schizophrenia |
| RDN-929 | Phase 1 | Healthy |
| Samidorphan | Phase 1 | Healthy Volunteers |
Latest
- alkermes filed 8-K
- Positive Top-line Results: alkermes
- alkermes filed 8-K
- alkermes filed 8-K
- alkermes filed 8-K
Follow Alkermes on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.